OPG can prevent the association between TRAIL and its death-inducing receptor, thereby increasing the survival of tumour cells that have metastasised to the bone microenvironment29, 51, 52; this may be one reason that OPG levels increase when tumours metastasise to bone. This evidence concerns the gene TNFSF10 and neoplasm.